Searchable abstracts of presentations at key conferences in endocrinology

ea0026p61 | Endocrine tumours and neoplasia | ECE2011

Liposome based strategies for the treatment of adrenocortical carcinoma

Hantel C , Lewrick F , Reincke M , Suss R , Beuschlein F

Medical treatment of adrenocortical carcinoma (ACC) is limited to common cytotoxic agents, which are usually given in combination with mitotane. Recently we have developed a novel therapeutic approach by coupling a monoclonal IGF1 receptor blocking antibody (1H7) to sterically stabilized liposomal doxorubicin (SSLD). 1H7 coupled liposomes showed in vitro high and significant cellular association and furthermore internalization in various human tumor cell lines as well a...

ea0029p1 | Adrenal cortex | ICEECE2012

Targeting mutated β-catenin in vitro and in vivo inhibits cell proliferation and stimulates apoptosis: a promising therapeutic target in adrenocortical carcinoma

Ragazzon B. , Gaujoux S. , Hantel C. , Tissier F. , Rizk-Rabin M. , Beuschlein F. , Bertherat J.

Adrenocortical carcinoma (ACC) is a rare and highly aggressive endocrine neoplasm, with limited therapeutic option. Activating β-catenin somatic mutations are observed in ACC and associated with a poor outcome. Activation of the Wnt/β-catenin signaling pathway seems to play a major role in ACC aggressiveness, and might be a promising therapeutic target. The H295 cell line derived from an ACC harbors an activating β-catenin mutation. We herein assess the in vi...

ea0029p815 | Endocrine tumours and neoplasia | ICEECE2012

Differential TNFα -synthesis and signaling in endocrine tumors after treatment with the Tumor-Vascular-Disrupting Agent ASA404 (vadimezan)

Hantel C. , Ozimek A. , Frantsev R. , Scheller F. , Reincke M. , Mussack T. , Beuschlein F.

Recently, we investigated effects of the Tumor-VDA ASA404 in tumor models for neuroendocrine tumors of the gastroenteropancreatic system and adrenocortical carcinoma 24 hours after treatment of BON and NCIh295 tumor bearing mice with ASA404 (A), paclitaxel (P) or the combination (A+P). We detected for BON tumors extensive necrotic areas as well as a significant decrease in cell proliferation, increase of apoptotic cells and reduction of microvessels after A or A+P treatment wh...

ea0026p60 | Endocrine tumours and neoplasia | ECE2011

Development and characterisation of patient-individual tumor models for endocrine tumors

Hantel C , Scheller F , Ozimek A , Chiapponi C , Mussack T , Beuschlein F

Only a few cell lines are available for endocrine tumors which furthermore do not reflect heterogenous functional properties and specific therapeutic response rates of individual tumors. To facilitate patient individual treatments and thereby to optimize therapeutic efficacy, we are aiming at the development and characterisation of patient-individual tumor models. Pieces of surgical tumor specimen from four adrenocortical carcinomas, one aldosterone producing adenoma, one pheo...